Engineered extracellular vesicle capable of efficiently knocking down expression level of target gene and preparation method therefor

By linking the NLS peptide to the N-terminus of the AGO2 protein to form engineered extracellular vesicles of nucleic acid-protein complexes, the problems of high immunogenicity and low gene knockdown efficiency in existing extracellular vesicle delivery systems are solved, achieving highly efficient and low-toxicity target gene silencing, which is suitable for the treatment of various disease-related genes.

WO2026238069A1PCT designated stage Publication Date: 2026-11-19VESICURE THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/097045
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-16
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing extracellular vesicle delivery systems suffer from high immunogenicity, low biocompatibility, and low gene knockdown efficiency when loading small nucleic acids, which limits their application prospects in disease treatment.

Method used

An engineered extracellular vesicle was designed by linking an NLS polypeptide to the N-terminus of the AGO2 protein to form a nucleic acid-protein complex consisting of a small nucleic acid guide strand, the AGO2 protein, and the NLS polypeptide. The complex was enriched and loaded using donor cells, and the guide strand was enriched and entered into the extracellular vesicle through a specially designed small nucleic acid precursor sequence, achieving targeted delivery and silencing.

Benefits of technology

It significantly improves the knockdown efficiency of target genes, reduces cytotoxicity, and is suitable for knocking down different target genes, including inflammation-related genes, immune regulation genes, and lipid metabolism-related genes. It has low immunogenicity and high biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026097045_19112026_PF_FP_ABST
    Figure CN2026097045_19112026_PF_FP_ABST
Patent Text Reader

Abstract

An engineered extracellular vesicle capable of efficiently knocking down the expression level of a target gene and a preparation method therefor. The engineered extracellular vesicle capable of efficiently knocking down the expression level of a target gene comprises an extracellular vesicle and a nucleic acid protein complex encapsulated in the extracellular vesicle, wherein the nucleic acid protein complex consists of a guide strand of a small nucleic acid, an AGO2 protein, and an NLS polypeptide, the guide strand of the small nucleic acid binds to the AGO2 protein by means of non-covalent interaction, the NLS polypeptide is linked to the N-terminus of the AGO2 protein, and the guide strand of the small nucleic acid can specifically bind to the mRNA of the target gene in a targeted manner by means of complementary base pairing. The obtained engineered extracellular vesicle significantly improves the target gene knockdown efficiency while significantly reducing cytotoxicity.
Need to check novelty before this filing date? Find Prior Art

Description

An engineered extracellular vesicle capable of efficiently knocking down target gene expression levels and its preparation method Technical Field

[0001] This invention belongs to the field of molecular biology technology, specifically relating to an engineered extracellular vesicle that can efficiently knock down the expression level of target genes and its preparation method. Background Technology

[0002] The strategy of knocking down gene expression levels using small nucleic acids such as siRNA, saRNA, ASO, shRNA, and miRNA is showing great potential in the field of disease treatment. Because the backbone of small nucleic acids carries a large negative charge, they have difficulty crossing the cell membrane barrier and entering cells, thus requiring the assistance of delivery systems. Current small nucleic acid delivery systems mainly include LNP platforms, GalNAc platforms, peptide-conjugated platforms, and antibody-conjugated platforms. These platforms rely entirely on chemical synthesis, chemical conjugation, and chemical modification, thus suffering from high immunogenicity and low biocompatibility.

[0003] Extracellular vesicles, as cellularly secreted nanovesicles, possess low immunogenicity and high biocompatibility, making them a promising novel delivery platform for small nucleic acids. Currently, several methods for loading and delivering small nucleic acids using extracellular vesicles have been reported, such as electroporation, co-incubation, chemical transfection, and sonication, to exogenously load small nucleic acids into extracellular vesicles. However, the gene knockdown efficiency achieved by these methods is generally low, thus limiting their application prospects. Summary of the Invention

[0004] The technical problem to be solved by the present invention is to provide an engineered extracellular vesicle that can effectively knock down the expression level of target genes.

[0005] The first aspect of the present invention provides an engineered extracellular vesicle for knocking down the expression level of a target gene, comprising an extracellular vesicle and a nucleic acid-protein complex contained in the extracellular vesicle, the nucleic acid-protein complex being composed of a guide strand of a small nucleic acid, an AGO2 protein, and an NLS polypeptide, wherein the guide strand of the small nucleic acid binds to the AGO2 protein through a non-covalent interaction, the NLS polypeptide is attached to the N-terminus of the AGO2 protein, and the guide strand of the small nucleic acid is designed to specifically bind to the mRNA of the target gene through complementary base pairing.

[0006] The engineered extracellular vesicles of this invention are generated from donor cells and are enriched with nucleic acid-protein complexes. The nucleic acid cargo that forms the nucleic acid-protein complexes is a guide strand RNA. Through the special design of the small nucleic acid precursor sequence, this invention ensures that only the guide strand of the small nucleic acid generated in the donor cells is enriched and enters the extracellular vesicles, whereas the traditional small nucleic acid precursor sequence design would cause both the guide strand and the transit strand to enter the extracellular vesicles simultaneously.

[0007] The guide strand of the small nucleic acid and the AGO2 protein (Argonaute-2 protein) are crucial for RNA-induced silencing complex (RISC)-mediated gene silencing. The AGO2 protein connects to the guide strand of the small nucleic acid, directing RISC to target mRNA for silencing. Our research shows that direct use of wild-type AGO2 protein, due to its cytoplasmic localization, leads to high target cell toxicity.

[0008] The NLS polypeptide is an amino acid sequence that guides protein transport to the cell nucleus. It can interact with the nuclear pore complex, thereby transporting the protein into the nucleus. In embodiments of the present invention, the NLS polypeptide is linked to the N-terminus of the AGO2 protein, causing the overexpressed AGO2 protein to be localized to the cell nucleus. This significantly reduces toxicity to target cells. Furthermore, the research results of the present invention show that only when the NLS polypeptide is linked to the N-terminus of the AGO2 protein can the knockdown efficiency of the target gene be significantly improved.

[0009] This invention can be used for the knockdown of different target genes, including but not limited to inflammation-related genes, immune-regulating genes, and lipid metabolism-related genes. Specifically, inflammation-related genes include Myd88, STAT6, and iNOS genes; immune-regulating genes include HLA-DM, TNF, HSP70, PSMB, and Bf genes; and lipid metabolism-related genes include CRP, TP63, YP1A1, and ADIPOQ genes.

[0010] According to the present invention, the AGO2 protein can be any AGO2 protein known in the art that is capable of forming a RISC with the guide strand of a small nucleic acid, including but not limited to human AGO2 protein, the amino acid sequence of which is shown in SEQ ID NO:29.

[0011] In an embodiment of the present invention, the nucleotide sequence encoding the AGO2 protein is shown in SEQ ID NO:12.

[0012] According to the present invention, the NLS polypeptide includes an NLS polypeptide capable of transporting AGO2 protein to the cell nucleus after the engineered extracellular vesicles deliver the nucleic acid-protein complex to the cell.

[0013] In embodiments of the present invention, the NLS polypeptide is preferably derived from the T antigen of monkey kidney virus (SV40) (SV40-NLS), and its amino acid sequence is PKKKRK. In other embodiments, the NLS polypeptide may also be a nucleoplasmin-NLS, and its amino acid sequence is KRPAATKKAGQAKKKK.

[0014] According to the present invention, when referring to an amino acid sequence, unless specifically defined otherwise, the referred amino acid sequence includes not only sequences that are exactly identical to the sequence, but also those sequences that are readily conceived by a person skilled in the art based on the sequence and that can be expected to have equivalent effects (e.g., a person skilled in the art should know that sequences with high consistency (e.g., more than 85%, especially more than 90%, particularly more than 95%) generally have equivalent effects).

[0015] According to the present invention, the small nucleic acids include, but are not limited to, siRNA, saRNA, ASO, shRNA, and miRNA.

[0016] In embodiments of the present invention, the length of the guide strand of the small nucleic acid is 18 to 30 nt, for example 18 nt, 19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, 25 nt, 26 nt, 27 nt, 28 nt, 29 nt, or 30 nt, and the length of the guide strand of the small nucleic acid is preferably 20 to 25 nt.

[0017] In some specific embodiments of the present invention, the target gene is the Myd88 gene, and the sequence of the guide strand of the small nucleic acid is TTTAATAGGAATCAGTCGCTT.

[0018] In some other specific embodiments of the present invention, the target gene is the STAT6 gene, and the sequence of the guide strand of the small nucleic acid is GCAGTACACTCATGGACTCTT.

[0019] In some further embodiments of the present invention, the target gene is the iNOS gene, and the sequence of the guide strand of the small nucleic acid is CTGGATCTTGACCATCAGCTT.

[0020] A second aspect of the present invention provides an engineered cell for preparing the above-mentioned engineered extracellular vesicles, the engineered cell comprising a first exogenous nucleic acid fragment encoding a guide strand of the small nucleic acid, a transit strand of the small nucleic acid and a ribozyme with self-cleaving activity, and a second exogenous nucleic acid fragment encoding the NLS polypeptide and the AGO2 protein, wherein the guide strand of the small nucleic acid and the transit strand of the small nucleic acid can form a stem-loop structure through reverse complementary base pairing, and the ribozyme is connected to the 3' end of the transit strand of the small nucleic acid.

[0021] The ribozymes available in this invention are selected from HDV ribozymes, hairpin ribozymes, and hammerhead ribozymes. HDV ribozymes are preferred, with the coding sequence CATGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGCGCCGGCTGGGCAACATTCCGAGGGGACCGTCCCCTCGGTAATGGCGAATGGGACC.

[0022] According to the present invention, the ring in the stem-ring structure is located at one end of the stem. According to the present invention, the ribozyme is located at the other end of the stem.

[0023] According to the present invention, the guest strand of the small nucleic acid is 3-6 nt shorter than the leader strand of the small nucleic acid, for example, 3nt, 4nt, 5nt, or 6nt. When the leader strand and the guest strand of the small nucleic acid pair through reverse complementary base pairing, the 3' end of the guest strand aligns with the 5' end of the leader strand, and the 3-6 nt portion of the leader strand that is not paired with the guest strand forms a loop, and the ribozyme connects to the 3' end of the guest strand.

[0024] In an embodiment of the present invention, the engineered cell is a mammalian cell.

[0025] According to the present invention, the mammalian cells involved include, but are not limited to, cells of mammals commonly found in the art, such as those of cattle, pigs, camels, llamas, horses, goats, rabbits, sheep, hamsters, guinea pigs, cats, dogs, rats, and mice; cells of non-human primates, such as monkeys, such as cynomolgus monkeys or rhesus monkeys, and chimpanzees; and cells of humans, including but not limited to those of humans. The mammalian cells involved include cells of transgenic mammals.

[0026] Specifically, mammalian cells include, but are not limited to, fibroblast cell lines, embryonic kidney cell lines, kidney cell lines, mesenchymal stem cell lines, and megakaryocyte cell lines. Exemplary mammalian cells include Chinese hamster ovary (CHO cells), human embryonic kidney 293 cells (e.g., HEK293, HEK293F, HEK293E, HEK293T), COS cells, BHK cells, NIH3T3 cells, mammary epithelial cells, adipose-derived mesenchymal stem cells, umbilical cord mesenchymal stem cells, or placental mesenchymal stem cells, etc.

[0027] In an embodiment of the present invention, the sequence of the second exogenous nucleic acid fragment is shown in SEQ ID NO:6.

[0028] According to the present invention, the small nucleic acids include, but are not limited to, siRNA, saRNA, ASO, shRNA, and miRNA.

[0029] In some specific embodiments of the present invention, the small nucleic acid is siRNA targeting the Myd88 gene, and the sequence of the first exogenous nucleic acid fragment is shown in SEQ ID NO:23.

[0030] In some other specific embodiments of the present invention, the small nucleic acid is siRNA targeting the STAT6 gene, and the sequence of the first exogenous nucleic acid fragment is shown in SEQ ID NO:25.

[0031] In some further embodiments of the present invention, the small nucleic acid is siRNA targeting the iNOS gene, and the sequence of the first exogenous nucleic acid fragment is shown in SEQ ID NO:27.

[0032] A third aspect of the present invention also provides a method for preparing the above-mentioned engineered extracellular vesicles, comprising the following steps:

[0033] (1) Construct small nucleic acid precursor expression plasmids and protein expression plasmids.

[0034] The expression cassette of the small nucleic acid precursor expression plasmid, from upstream to downstream, includes: a promoter, a guide strand sequence of the small nucleic acid, a guest strand sequence of the small nucleic acid, a sequence of a ribozyme with self-cleavage activity, and a terminator. The guide strand of the small nucleic acid can specifically bind to the mRNA of the target gene through base complementarity pairing, and the guest strand of the small nucleic acid can form a stem-loop structure with the guide strand of the small nucleic acid through reverse base complementarity pairing.

[0035] The expression cassette of the protein expression plasmid, from upstream to downstream, includes: a promoter, an NLS polypeptide, an AGO2 sequence, and a terminator.

[0036] (2) The small nucleic acid precursor expression plasmid and the protein expression plasmid were used to transfect cells simultaneously or sequentially to obtain engineered cells;

[0037] (3) The engineered cells are cultured to obtain a cell culture medium;

[0038] (4) The engineered extracellular vesicles are isolated from the cell culture medium.

[0039] According to the present invention, the target genes include target genes known in the art that are associated with the development of various diseases, including but not limited to inflammation-related genes, immune-regulating genes, and lipid metabolism-related genes. Specifically, inflammation-related genes include, for example, the Myd88 gene, the STAT6 gene, and the iNOS gene; immune-regulating genes include, for example, the HLA-DM gene, the TNF gene, the HSP70 gene, the PSMB gene, and the Bf gene; and lipid metabolism-related genes include, for example, the CRP gene, the TP63 gene, the YP1A1 gene, and the ADIPOQ gene.

[0040] According to the present invention, the ring in the stem-ring structure is located at one end of the stem. According to the present invention, the ribozyme is located at the other end of the stem.

[0041] According to the present invention, the guest strand of the small nucleic acid is 3-6 nt shorter than the leader strand of the small nucleic acid, for example, 3nt, 4nt, 5nt, or 6nt. When the guest strand and the leader strand of the small nucleic acid are paired by reverse complementary base pairing, the 3' end of the guest strand aligns with the 5' end of the leader strand, and the 3-6 nt portion of the leader strand that is not paired with the guest strand forms a loop, and the ribozyme is connected to the 3' end of the guest strand.

[0042] According to the present invention, the AGO2 protein can be any known in the art, mutated or unmutated AGO2 protein capable of forming a RISC with the guide strand of a small nucleic acid, including but not limited to human AGO2 protein, the amino acid sequence of which is shown in SEQ ID NO:29.

[0043] In an embodiment of the present invention, the nucleotide sequence encoding the AGO2 protein is shown in SEQ ID NO:12.

[0044] According to the present invention, the NLS polypeptide includes an NLS polypeptide capable of transporting AGO2 protein to the cell nucleus after the engineered extracellular vesicles deliver the nucleic acid-protein complex to the cell.

[0045] In embodiments of the present invention, the NLS polypeptide is preferably derived from the T antigen of monkey kidney virus (SV40) (SV40-NLS), and its amino acid sequence is PKKKRK. In other embodiments, the NLS polypeptide may also be a nucleoplasmin-NLS, and its amino acid sequence is KRPAATKKAGQAKKKK.

[0046] According to the present invention, the small nucleic acids include, but are not limited to, siRNA, saRNA, ASO, shRNA, and miRNA.

[0047] In embodiments of the present invention, the length of the guide strand of the small nucleic acid is 18–30 nt, for example, 18 nt, 19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, 25 nt, 26 nt, 27 nt, 28 nt, 29 nt, or 30 nt, and preferably 19–25 nt. The guest strand of the small nucleic acid is 3–6 nt shorter than the length of the guide strand, for example, 3 nt, 4 nt, 5 nt, or 6 nt. Preferably, the length of the guest strand of the small nucleic acid is 15–22 nt, for example, 15 nt, 16 nt, 17 nt, 18 nt, 19 nt, 20 nt, 21 nt, or 22 nt, and preferably 16–19 nt.

[0048] In embodiments of the present invention, the ribozyme is selected from HDV ribozymes, hairpin ribozymes, and hammerhead ribozymes. Preferably, it is an HDV ribozyme with the coding sequence CATGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGCGCCGGCTGGGCAACATTCCGAGGGGACCGTCCCCTCGGTAATGGCGAATGGGACC.

[0049] In the embodiments of the present invention, the plasmids used for the small nucleic acid precursor expression plasmid and the protein expression plasmid are expression vectors conventionally used in the art, including viral plasmid vectors and eukaryotic expression plasmid vectors, preferably eukaryotic expression plasmid vectors, such as pAAVS1 plasmid, pIRES plasmid, or pLENTI plasmid.

[0050] In this embodiment of the invention, the separation can be performed using extracellular vesicle separation and purification methods known in the art, including one or more of ultracentrifugation, density gradient centrifugation, size exclusion chromatography, affinity chromatography, adsorption chromatography, bonded phase chromatography, immunoassay, or sieving.

[0051] According to some embodiments of the present invention, the cell culture medium is first centrifuged at a centrifugal force of less than 1000g, and the supernatant is collected. Then, the supernatant is centrifuged at a centrifugal force of 100000g to 200000g, and the precipitate is collected, which is the engineered extracellular vesicle.

[0052] Further, the cell culture medium is first centrifuged at a centrifugal force of 200g to 500g, and the supernatant is collected. Then, the supernatant is centrifuged at a centrifugal force of 120000g to 150000g, and the precipitate is collected, which is the engineered extracellular vesicle.

[0053] In this embodiment of the invention, the cell culture medium is a serum-free culture medium.

[0054] In this embodiment of the invention, the engineered cells are cultured at 34°C to 38°C and 5% to 10% CO2 to obtain the cell culture medium.

[0055] In this embodiment of the invention, the transfection operation involves mixing the small nucleic acid precursor expression plasmid and protein expression plasmid, the cells to be transfected, and the transfection reagent in a serum-free culture medium and incubating at 20°C to 30°C.

[0056] According to some specific embodiments of the present invention, the transfected cells are selected from CHO cells, HEK293 cells, COS cells, mammary epithelial cells, adipose-derived mesenchymal stem cells, umbilical cord mesenchymal stem cells, and placental mesenchymal stem cells.

[0057] According to some specific embodiments of the present invention, the expression vectors used for the small nucleic acid precursor expression plasmid and the protein expression plasmid are independently pAAVS1 plasmid, pIRES plasmid or pLENTI plasmid.

[0058] According to some specific embodiments of the present invention, the promoter of the small nucleic acid precursor expression plasmid is the U6 promoter, and the terminator is a polyT sequence.

[0059] According to some specific embodiments of the present invention, the promoter of the protein expression plasmid is the CAG promoter, and the terminator is the BgH sequence.

[0060] A third aspect of the present invention also provides a plasmid expression system for preparing the above-mentioned engineered extracellular vesicles, comprising the above-mentioned small nucleic acid precursor expression plasmid and protein expression plasmid.

[0061] A fourth aspect of the present invention also provides a nucleic acid drug comprising the above-described engineered extracellular vesicles, optionally including pharmaceutically acceptable excipients.

[0062] The engineered extracellular vesicles described in this invention include exosomes, microvesicles, or apoptotic bodies produced by engineered cells.

[0063] In embodiments of the present invention, specific excipients may be selected according to the intended administration mode and therapeutic application, and the pharmaceutically acceptable excipients include, but are not limited to, pharmaceutically, nutritionally, or physiologically acceptable carriers.

[0064] Furthermore, the nucleic acid drugs include, but are not limited to, tablets, granules, pills, capsules, emulsions, ointments, gels, suspensions, solutions, powders, transdermal patches, sprays, suppositories, or implants.

[0065] A fifth aspect of the present invention provides a kit comprising the engineered extracellular vesicles described above, or the nucleic acid drug described above.

[0066] The sixth aspect of the present invention provides a method for diagnosing, preventing or treating a disease, the method comprising administering the engineered extracellular vesicles or the nucleic acid drug described above to a subject.

[0067] In this embodiment of the invention, the specific disease to be detected, prevented or treated by the engineered extracellular vesicles is preferably determined based on the target gene corresponding to the small nucleic acid, including but not limited to various inflammatory diseases.

[0068] By adopting the above technical solution, the present invention has the following advantages compared with the prior art:

[0069] The engineered extracellular vesicles of the present invention contain a nucleic acid-protein complex enriched and loaded with a small nucleic acid guide strand, an AGO2 protein, and an NLS polypeptide linked to the N-terminus of the AGO2 protein. This complex not only exhibits low cytotoxicity but also high knockdown efficiency against target genes. Attached Figure Description

[0070] Figure 1 shows the particle size distribution of the engineered extracellular vesicles in Example 1;

[0071] Figure 2 shows the particle size distribution of the engineered extracellular vesicles in Comparative Example 1.

[0072] Figure 3 shows the particle size distribution of the engineered extracellular vesicles in Comparative Example 2.

[0073] Figure 4 shows the particle size distribution of the engineered extracellular vesicles in Comparative Example 3.

[0074] Figure 5 shows the particle size distribution of the engineered extracellular vesicles in Comparative Example 4.

[0075] Figure 6 is a transmission electron microscope image of the engineered extracellular vesicles of Example 1;

[0076] Figure 7 is a transmission electron microscope image of the engineered extracellular vesicles in Comparative Example 1.

[0077] Figure 8 is a transmission electron microscope image of the engineered extracellular vesicles of Comparative Example 2.

[0078] Figure 9 is a transmission electron microscope image of the engineered extracellular vesicles of Comparative Example 3.

[0079] Figure 10 is a transmission electron microscope image of the engineered extracellular vesicles in Comparative Example 4.

[0080] Figure 11 shows the effect of high doses on the fluorescence intensity of reporter cells by engineered extracellular vesicles of Example 1 and Comparative Examples 2-4.

[0081] Figure 12 shows the effect of engineered extracellular vesicles of Example 1 and Comparative Examples 2-4 on EGFP expression in reporter cells at high doses.

[0082] Figure 13 shows the effect of engineered extracellular vesicles from Comparative Examples 1-2 on the fluorescence intensity of reporter cells at low doses.

[0083] Figure 14 shows the effect of engineered extracellular vesicles from Comparative Examples 1-2 on EGFP expression in reporter cells at low doses.

[0084] Figure 15 shows the RNA-seq analysis results of reporter cells that received engineered extracellular vesicles from Example 1.

[0085] Figure 16 shows the particle size distribution of the engineered extracellular vesicles in Example 2;

[0086] Figure 17 is a transmission electron microscope image of the engineered extracellular vesicles of Example 2;

[0087] Figure 18 shows the effect of engineered extracellular vesicles on the expression level of the Myd88 gene in reporter cells in Example 2.

[0088] Figure 19 shows the effect of engineered extracellular vesicles in Example 2 on the levels of different pro-inflammatory cytokines in reporter cells;

[0089] Figure 20 shows the particle size distribution of the engineered extracellular vesicles in Example 3;

[0090] Figure 21 is a transmission electron microscope image of the engineered extracellular vesicles of Example 3;

[0091] Figure 22 shows the effect of engineered extracellular vesicles on the expression level of STAT6 gene in reporter cells in Example 3.

[0092] Figure 23 shows the effect of engineered extracellular vesicles of Example 3 on the levels of different pro-inflammatory cytokines in reporter cells.

[0093] Figure 24 shows the particle size distribution of the engineered extracellular vesicles in Example 4;

[0094] Figure 25 is a transmission electron microscope image of the engineered extracellular vesicles of Example 4;

[0095] Figure 26 shows the effect of engineered extracellular vesicles on the expression level of iNOS gene in reporter cells in Example 4.

[0096] Figure 27 is a schematic diagram of the modeling process and pulmonary nebulization drug delivery procedure for an acute lung injury model.

[0097] Figure 28 shows the effect of engineered extracellular vesicles of Example 4 on the levels of two pro-inflammatory cytokines in experimental mice.

[0098] Figure 29 shows lung sections and HE staining results of experimental mice. Detailed Implementation

[0099] This study found that when both the guide strand and the transit strand of small nucleic acids (SRNAs) are enriched in extracellular vesicles used for delivery (e.g., siRNA, miRNA), the knockdown level of the target gene in the guide strand of the SRNA is significantly lower. Furthermore, the AGO2 protein is an effective linker for loading small nucleic acids or their guide strands; however, in some specific experiments using AGO2 as a linker, high cytotoxicity was observed. Based on the in-depth research results of this application, it is speculated that the high cytotoxicity is due to the fact that the AGO2 protein, acting as a linker, is localized in the cytoplasm in these experiments, potentially interacting with endogenous double-stranded RNA (dsRNA) and the RISC complex, thereby affecting the endogenous gene silencing pathway and leading to high cytotoxicity. Extensive exploration was conducted to address this issue, ultimately discovering that linking an NLS peptide to the N-terminus of the AGO2 protein is an effective pathway to localize the AGO2 protein to the nucleus, thereby reducing cytotoxicity.

[0100] Based on this, this application proposes an engineered extracellular vesicle scheme for loading an extracellular vesicle into a nucleic acid-protein complex consisting of a guide strand of a small nucleic acid, an AGO2 protein, and an NLS polypeptide, with the NLS polypeptide linked to the N-terminus of the AGO2 protein.

[0101] The technical solution of the present invention will be further described below with reference to specific embodiments and comparative examples.

[0102] In this invention, it should be noted that, unless otherwise stated or contradicted by the context, the terms or expressions used herein should be read in conjunction with the entire text and as understood by one of ordinary skill in the art. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0103] Extracellular vesicles are vesicle-like bodies with a double membrane structure that detach from the cell membrane or are secreted by the cell. They range in diameter from 40 nm to 1000 nm and can be classified into exosomes, microvesicles, and apoptotic bodies according to their size.

[0104] "Engineering extracellular vesicles" refers to extracellular vesicles produced by cells after artificial intervention or by cells after genetic engineering modification.

[0105] "Small nucleic acid" is a short RNA molecule designed to bind to the mRNA of a target gene and inhibit its translation and expression. It consists of a guide strand and a guest strand. The guide strand is a strand that is complementary to the target gene to a certain extent, and the guest strand is a strand that is complementary to the guide strand.

[0106] In the RNA interference pathway, the AGO2 protein can bind to small nucleic acids to form an RNA-induced silencing complex (RISC), leading to the degradation or translational repression of target mRNA. This process is known as RNAi.

[0107] "NLS", also known as nuclear localization sequence or nuclear localization signal, is present in nucleophiles and enables the nucleophiles to be transported into the cell nucleus through the nuclear pore complex.

[0108] "Exogenous nucleic acid fragments" include any gene or fragment thereof of interest, such as a gene or fragment encoding a scaffold protein. Exogenous nucleic acid fragments have a different origin from the donor cell; for example, they are nucleic acid sequences isolated from an organism different from the donor cell, i.e., they are exogenous nucleic acid fragments relative to the donor cell.

[0109] "Plasmid" refers to a circular double-stranded DNA that can accept exogenous nucleic acid fragments and replicate in prokaryotic or eukaryotic cells.

[0110] A promoter is a nucleic acid sequence that controls the transcription of a coding sequence. Promoter sequences include modified sequences that enable RNA polymerase to recognize, bind to, and initiate transcription. Promoters can affect the transcription of genes located on the same nucleic acid molecule as themselves or genes located on different nucleic acid molecules.

[0111] "Myd88" refers to myeloid differentiation protein 88, which plays a crucial role in signal transduction and immune responses. For example, in LPS-mediated acute inflammation, after LPS is recognized by the TLR4 receptor, the signal is transmitted downstream via Myd88, leading to a massive release of inflammatory cytokines. Knocking down the expression level of the Myd88 gene can inhibit the LPS-induced inflammatory response.

[0112] STAT6 refers to the STAT6 transcription factor, which participates in intracellular signal transduction and gene expression regulation. Overactivation of STAT6 in the tumor immune microenvironment often leads to immunosuppression and promotes tumor proliferation. Knocking down the expression level of the STAT6 gene in the tumor immune microenvironment can promote the release of inflammatory cytokines, enhance the infiltration of immune cells, and improve the tumor immune microenvironment.

[0113] The "iNOS gene" refers to inducible nitric oxide synthase, an isoenzyme present in cells that plays a major role in processes such as inflammatory responses, immune regulation, and apoptosis.

[0114] The implementation conditions used in the following examples and comparative examples can be further adjusted according to specific requirements. Unless otherwise specified, the implementation conditions are generally those used in routine experiments. Instruments, materials, and reagents, unless otherwise specified, are commercially available.

[0115] Example 1

[0116] This embodiment provides a method for preparing engineered extracellular vesicles capable of knocking down the EGFP gene. These extracellular vesicles are loaded with an EGFP guide strand RNA / NLS-AGO2 protein complex formed by EGFP guide strand RNA targeting EGFP and NLS-AGO2 protein, as detailed below:

[0117] 1. Preparation of small nucleic acid precursor expression plasmid and NLS-AGO2 protein expression plasmid

[0118] (1) Constructing small nucleic acid precursor expression plasmid and NLS-AGO2 protein expression plasmid

[0119] Constructing a small nucleic acid precursor expression plasmid: using pIRES plasmid as the expression vector, the expression cassette was designed as follows: using the U6 promoter (sequence shown in SEQ ID NO:1) as the transcription start point, using the polyT sequence (sequence TTTTTTT, SEQ ID NO:2) as the transcription end point, and containing the sequence for expressing the small nucleic acid precursor (sequence shown in SEQ ID NO:3, 21nt guide strand sequence + 17nt guest strand sequence + 88nt HDV ribozyme sequence).

[0120] Constructing the NLS-AGO2 protein expression plasmid: using pIRES plasmid as the expression vector, the expression cassette was designed as follows: using the CAG promoter (sequence shown in SEQ ID NO:4) as the transcription start point, using the BgH sequence (sequence shown in SEQ ID NO:5) as the transcription end point, and containing the sequence for expressing the NLS-AGO2 protein (sequence shown in SEQ ID NO:6).

[0121] (2) PCR cloning: Using conventional methods in this field, upstream and downstream primers were designed according to the expression cassette, and upstream, downstream, and template DNA were synthesized. In a 0.2 mL EP tube, 25 μL of DNA polymerase (2×Phanta Max Master Mix, Vazyme, P515-01), 2 μL of upstream primer, 2 μL of downstream primer, and 10 g of template DNA were added. The volume was then brought to 50 μL with enzyme-free water (RNase-free dd H2O, Vazyme, P071-01-AA), mixed thoroughly, and placed in a PCR instrument. An amplification program was designed according to the primer annealing temperature. The upstream primer sequence of the small nucleic acid precursor expression plasmid is shown in SEQ ID NO:7, the downstream primer sequence is shown in SEQ ID NO:8, and the template DNA sequence is shown in SEQ ID NO:3. The upstream primer sequence of the NLS-AGO2 protein expression plasmid is shown in SEQ ID NO:9, the downstream primer sequence is shown in SEQ ID NO:10, and the template DNA sequence is shown in SEQ ID NO:6.

[0122] (3) Purification of PCR products: Purify PCR products according to the kit instructions (Vazyme, DC301-01).

[0123] (4) Enzyme digestion: Add 5 μL rCutSmart to a 0.2 mL EP tube. TM Buffer (BioLabs, 136004s), 0.5 μL P Ac I enzyme (BioLabs, R0547L), 0.5 μL Not I enzyme (BioLabs, R3189L), 2 μg of PCR purified fragment, and 5 μg pAAVS1 vector plasmid were prepared. The mixture was brought to a final volume of 10 μL with enzyme-free water (RNase-free ddH2O, Vazyme, P071-01-AA), mixed thoroughly, and then incubated in a PCR instrument at 37°C for 16 h for enzyme digestion.

[0124] (5) Ligation and transformation: In a 0.2 mL EP tube, add 4 μL of the enzyme digestion solution obtained in step (3), 1 μL of T4 DNA ligase (Vazyme, N103-01-AA), and 1 μL of T4 DNA ligase buffer (Vazyme, N103-01-AC). After incubating at room temperature for 10 min, add 5 μL to competent cells (DH5α, Vazyme, C502-03), incubate on ice for 30 min, incubate at 42℃ for 90 s, incubate on ice for 2 min, and then add 1 mL of LB medium (BeyoPure). TM(04.05.ST156) Place in a shaking incubator and incubate for 1 hour. After incubation, centrifuge at 12000g for 1 minute, remove the supernatant and resuspend 100μL in a bacterial culture dish (Biosharp, BS-90-D), then spread evenly with a disposable plastic spreader (Biosharp, BS-PS-A) and store in a 37℃ constant temperature incubator for later use.

[0125] 2. Cell transfection

[0126] The specific steps are as follows:

[0127] (1) Preparing cells for transfection

[0128] EXPI293F cells were seeded at a concentration of 1.5E+6 / mL, with a viability of over 95%, in 125mL shake flasks with a total volume of 25mL serum-free cell culture medium (Opmai medium, CD05). The flasks were incubated overnight at 37°C and 100rpm in an 8% CO2 constant-temperature shaker. Transfection began the following day.

[0129] (2) PEI transfection

[0130] The transfection process using TA293 reagent (Zhuhai Kairui Biotechnology Co., Ltd., K2001) is as follows:

[0131] The target plasmid was extracted from the transformed competent cells preserved by the above-mentioned plating culture using conventional techniques in the art, thus obtaining the constructed small nucleic acid precursor expression plasmid and NLS-AGO2 protein expression plasmid. Two 15 mL centrifuge tubes were prepared. In one tube, 1.25 mL of serum-free cell culture medium and 25 μg of the target plasmid were added, and the mixture was vortexed. In the other tube, 1.25 mL of serum-free cell culture medium and 125 μL of TA293 transfection reagent were added, and the mixture was vortexed. All liquid in the centrifuge tube containing the transfection reagent was transferred to the centrifuge tube containing the target plasmid, and the mixture was vortexed. The cells were incubated at room temperature for 10 minutes to prepare the plasmid-vector complex. EXPI293F cells were removed from the constant-temperature shaker, and the prepared plasmid-vector complex was added dropwise while shaking. The cells were then returned to the 8% CO2 constant-temperature shaker and cultured at 37°C and 100 rpm for 72 hours.

[0132] 3. Isolation and purification of exosomes

[0133] After 72 hours of shaking culture, the cell culture medium was first centrifuged at 300g, 4℃, and low speed for 5 min, and the supernatant was collected. Then, the supernatant was ultracentrifuged at 133900g, 4℃ for 1 h, and the precipitate was collected. The precipitate (i.e., the isolated extracellular vesicles loaded with the EGFP guide strand RNA / NLS-AGO2 complex) was resuspended in 100 μL PBS and stored at 4℃ for later use.

[0134] Comparative Example 1

[0135] This comparative example provides another method for preparing engineered extracellular vesicles capable of knocking down the EGFP gene, wherein the extracellular vesicles are loaded with a small nucleic acid / AGO2 protein complex.

[0136] In this comparative example, the sequence shown in SEQ ID NO:3 in the expression frame of the small nucleic acid precursor expression plasmid of Example 1 was replaced with the sequence shown in SEQ ID NO:11 (21nt guest strand sequence + 7nt linker + 21nt guide strand sequence).

[0137] In this comparative example, the NLS-AGO2 protein expression plasmid of Example 1 was replaced with the AGO2 protein expression plasmid, that is, the sequence expressing NLS-AGO2 protein in the expression frame of the NLS-AGO2 protein expression plasmid was replaced with the sequence expressing wild-type AGO2 protein (the sequence is shown in SEQ ID NO:12).

[0138] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:13), downstream primer (sequence shown in SEQ ID NO:14), and template DNA (sequence shown in SEQ ID NO:11) of the small nucleic acid precursor expression plasmid according to the adjusted expression cassette, and redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:15), downstream primer (sequence shown in SEQ ID NO:16), and template DNA (sequence shown in SEQ ID NO:12) of the AGO2 protein expression plasmid according to the adjusted expression cassette, the rest was carried out in accordance with Example 1, and extracellular vesicles loaded with small nucleic acid / AGO2 protein complex were finally obtained.

[0139] Comparative Example 2

[0140] This comparative example provides another method for preparing engineered extracellular vesicles capable of knocking down the EGFP gene. The engineered extracellular vesicles in this embodiment are loaded with an EGFP guide strand RNA / AGO2 protein complex.

[0141] In this comparative example, the small nucleic acid precursor expression plasmid of Example 1 was used. The NLS-AGO2 protein expression plasmid of Example 1 was replaced with the AGO2 protein expression plasmid, that is, the sequence expressing NLS-AGO2 protein in the expression frame of the NLS-AGO2 protein expression plasmid was replaced with the sequence expressing wild-type AGO2 protein (the sequence is shown in SEQ ID NO:12).

[0142] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:15), downstream primer (sequence shown in SEQ ID NO:16), and template DNA (sequence shown in SEQ ID NO:12) of the AGO2 protein expression plasmid according to the adjusted expression cassette, the rest was carried out in accordance with Example 1, and extracellular vesicles loaded with the EGFP guide strand RNA / AGO2 protein complex were finally obtained.

[0143] Comparative Example 3

[0144] This comparative example provides another method for preparing engineered extracellular vesicles capable of knocking down the EGFP gene. The engineered extracellular vesicles in this example are loaded with an EGFP guide strand RNA / AGO2-NLS protein complex.

[0145] In this comparative example, the small nucleic acid precursor expression plasmid of Example 1 was used. The NLS-AGO2 protein expression plasmid of Example 1 was replaced with the AGO2-NLS protein expression plasmid, that is, the sequence expressing NLS-AGO2 protein in the expression frame of the NLS-AGO2 protein expression plasmid was replaced with the sequence expressing AGO2-NLS protein (as shown in SEQ ID NO:17).

[0146] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:18), downstream primer (sequence shown in SEQ ID NO:19), and template DNA (sequence shown in SEQ ID NO:17) of the AGO2-NLS protein expression plasmid according to the adjusted expression cassette, the rest was carried out in accordance with Example 1, and extracellular vesicles loaded with the EGFP guide strand RNA / AGO2-NLS protein complex were finally obtained.

[0147] Comparative Example 4

[0148] This comparative example provides another method for preparing engineered extracellular vesicles capable of knocking down the EGFP gene. The engineered extracellular vesicles in this example are loaded with an EGFP guide strand RNA / NLS-AGO2-NLS protein complex.

[0149] In this comparative example, the small nucleic acid precursor expression plasmid of Example 1 was used. The NLS-AGO2 protein expression plasmid of Example 1 was replaced with the NLS-AGO2-NLS protein expression plasmid, that is, the sequence expressing NLS-AGO2 protein in the expression frame of the NLS-AGO2 protein expression plasmid was replaced with the sequence expressing NLS-AGO2-NLS (the sequence is shown in SEQ ID NO:20).

[0150] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:21), downstream primer (sequence shown in SEQ ID NO:22), and template DNA (sequence shown in SEQ ID NO:20) of the NLS-AGO2-NLS protein expression plasmid according to the adjusted expression cassette, the rest was carried out in accordance with Example 1, and extracellular vesicles loaded with the EGFP guide strand RNA / NLS-AGO2-NLS protein complex were finally obtained.

[0151] Extracellular vesicle identification:

[0152] (1) The engineered extracellular vesicles of the above examples and comparative examples were subjected to NTA analysis using a ZetaView instrument (Particle Metrix, catalog number N30E). The particle size distribution of the engineered extracellular vesicles of Example 1 and Comparative Examples 1-4 are shown in Figures 1-5, and the average particle size and median particle size are summarized in Table 1.

[0153] Table 1

[0154] Table 1 shows that the engineered extracellular vesicles in the examples and comparative examples all have particle sizes between 120 nm and 150 nm.

[0155] (2) The structures of engineered extracellular vesicles in Example 1 and Comparative Examples 1-4 were observed under a transmission electron microscope (TEM). As shown in Figures 6-10, typical vesicle structures were observed in Example 1 and Comparative Examples 1-4.

[0156] (3) Target gene knockdown efficiency analysis

[0157] The engineered extracellular vesicles of Examples 1 and Comparative Examples 2-4 were added in equal amounts (4E10 particles) to reporter cells containing green fluorescent protein. After incubation at 37°C and 5% CO2 for 48 hours, the fluorescence intensity was observed using a fluorescence microscope, and the gene expression level was detected by cell flow cytometry. The gene expression level of each treatment group was calculated with the expression level of the untreated group as 100%.

[0158] As shown in Figure 11, compared with the untreated group, the engineered extracellular vesicles in Comparative Example 2 caused a large number of cell deaths, while the engineered extracellular vesicles in Example 1 and Comparative Examples 3-4 had little effect on cell survival, indicating that the engineered extracellular vesicles in Comparative Example 2 had high cytotoxicity and the engineered extracellular vesicles in Example 1 and Comparative Examples 3-4 had high cell safety.

[0159] As shown in Figure 12, compared with the untreated group, the engineered extracellular vesicles in Example 1 reduced EGFP expression to 4%, the engineered extracellular vesicles in Comparative Example 2 reduced EGFP expression to 7.68%, the engineered extracellular vesicles in Comparative Example 3 reduced EGFP expression to 32.64%, and the engineered extracellular vesicles in Comparative Example 4 reduced EGFP expression to 47.37%.

[0160] Engineered extracellular vesicles from Comparative Example 1 and Comparative Example 2 were added in equal amounts (1E10 particles) to reporter cells containing green fluorescent protein. After incubation at 37°C and 5% CO2 for 48 hours, fluorescence intensity was observed using a fluorescence microscope, and gene expression levels were detected using flow cytometry. The gene expression levels of each treatment group were calculated with the expression level of the untreated group as 100%.

[0161] As shown in Figure 13, after reducing the dose, the engineered extracellular vesicles of Comparative Example 1 and Comparative Example 2 showed reduced cytotoxicity and increased cell viability compared to the high dose. The engineered extracellular vesicles of Comparative Example 2 showed better knockdown of cell target genes.

[0162] As shown in Figure 14, compared with the untreated group, the engineered extracellular vesicles in Comparative Example 1 reduced EGFP expression to 60.9%, and the engineered extracellular vesicles in Comparative Example 2 reduced EGFP expression to 26.9%.

[0163] As can be seen from Figures 11 to 14, the engineered extracellular vesicles of Example 1 can simultaneously achieve both cell safety and target gene knockdown, while the engineered extracellular vesicles of Comparative Examples 1 to 4 cannot achieve both.

[0164] (4)RNA-seq analysis

[0165] sRNA-seq analysis was performed on reporter cells that received the engineered extracellular vesicles from Example 1 to analyze the delivery of the guide and transit chains of small nucleic acids. As shown in Figure 15, the abundance of miR-16-5p, a classic marker of extracellular vesicles, in reporter cells was approximately 3000 TPM, the abundance of the guide chain of small nucleic acids (EGFP siRNA-AS) was approximately 1000 TPM, while the transit chain of small nucleic acids (EGFP siRNA-SS) was completely undetectable. This demonstrates that the engineered extracellular vesicles from Example 1 can specifically enrich and deliver the guide chain of small nucleic acids.

[0166] Example 2

[0167] This embodiment provides another method for preparing engineered extracellular vesicles capable of knocking down the Myd88 gene, wherein the extracellular vesicles are loaded with a Myd88 guide strand RNA / NLS-AGO2 protein complex formed by Myd88 guide strand RNA and NLS-AGO2 protein.

[0168] In this embodiment, the sequence shown in SEQ ID NO:3 in the expression frame of the small nucleic acid precursor expression plasmid of Example 1 is replaced with the small nucleic acid precursor expression sequence shown in SEQ ID NO:23 (21nt guide strand sequence + 17nt guest strand sequence + 88nt HDV ribozyme sequence). The NLS-AGO2 protein expression plasmid from Example 1 is used.

[0169] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:24), downstream primer (sequence shown in SEQ ID NO:8), and template DNA (sequence shown in SEQ ID NO:23) of the small nucleic acid precursor expression plasmid according to the adjusted expression cassette, the rest were carried out in accordance with Example 1, and the engineered extracellular vesicles loaded with the Myd88 guide strand RNA / NLS-AGO2 protein complex were finally obtained.

[0170] Extracellular vesicle identification:

[0171] The engineered extracellular vesicles of Example 2 were subjected to NTA analysis using a ZetaView instrument (Particle Metrix, catalog number N30E). The engineered extracellular vesicles of Example 2 were subjected to TEM analysis using transmission electron microscopy.

[0172] The particle size distribution of the engineered extracellular vesicles in Example 2 is shown in Figure 16, with an average particle size of 142.4 nm and a median particle size of 150.6 nm. As shown in Figure 17, the engineered extracellular vesicles in Example 2 exhibit typical vesicle structures.

[0173] Target gene knockdown efficiency analysis:

[0174] Using RAW264.7 macrophages as reporter cells, engineered extracellular vesicles from Example 2 with a total particle count of 1E10 were added to the culture medium. The expression level of the Myd88 gene was detected by qPCR, and the results are shown in Figure 18. With Myd88 gene expression in the untreated reporter cells as 100%, the engineered extracellular vesicles from Example 2 reduced Myd88 gene expression in the reporter cells to 11.3%.

[0175] Analysis of the inflammatory effect:

[0176] RAW264.7 macrophages were used as reporter cells. LPS was first added to the culture medium to induce the reporter cells to adopt the M1 pro-inflammatory phenotype, resulting in the secretion of large amounts of pro-inflammatory cytokines. Engineered extracellular vesicles from Example 2 with a total particle count of 1E10 were added to the culture medium, and the changes in the levels of different pro-inflammatory cytokines were detected by qPCR. The results are shown in Figure 19.

[0177] The engineered extracellular vesicles of Example 2 reduced IL-1β expression to 5.1%, IL-6 expression to 3.9%, IL-23 expression to 6.1%, and TNF-α expression to 5.7% in reporter cells. The engineered extracellular vesicles of Example 2 exhibited highly efficient anti-inflammatory effects.

[0178] Example 3

[0179] This embodiment provides another method for preparing engineered extracellular vesicles capable of knocking down the STAT6 gene. The extracellular vesicles are loaded with a STAT6 guide strand RNA targeting STAT6 and an NLS-AGO2 protein forming a STAT6 guide strand RNA / NLS-AGO2 protein complex.

[0180] In this embodiment, the sequence shown in SEQ ID NO:3 in the expression frame of the small nucleic acid precursor expression plasmid of Example 1 is replaced with the small nucleic acid precursor expression sequence shown in SEQ ID NO:25 (21nt guide strand sequence + 17nt guest strand sequence + 88nt HDV ribozyme sequence). The NLS-AGO2 protein expression plasmid from Example 1 is used.

[0181] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:26), downstream primer (sequence shown in SEQ ID NO:8), and template DNA (sequence shown in SEQ ID NO:25) of the small nucleic acid precursor expression plasmid according to the adjusted expression cassette, the rest were carried out in accordance with Example 1, and the engineered extracellular vesicles loaded with the STAT6 guide strand RNA / NLS-AGO2 protein complex were finally obtained.

[0182] Extracellular vesicle identification:

[0183] The engineered extracellular vesicles of Example 3 were subjected to NTA analysis using a ZetaView instrument (Particle Metrix, catalog number N30E). The engineered extracellular vesicles of Example 3 were subjected to TEM analysis using transmission electron microscopy.

[0184] The particle size distribution of the engineered extracellular vesicles in Example 3 is shown in Figure 20, with an average particle size of 154.8 nm and a median particle size of 164.0 nm. As shown in Figure 21, the engineered extracellular vesicles in Example 3 exhibit typical vesicle structures.

[0185] Target gene knockdown efficiency analysis:

[0186] Using RAW264.7 macrophages as reporter cells, engineered extracellular vesicles from Example 2 with a total particle count of 1E10 were added to the culture medium. The expression level of the STAT6 gene was detected by qPCR, and the results are shown in Figure 22. With STAT6 gene expression in the untreated reporter cells being 100%, the engineered extracellular vesicles from Example 3 reduced STAT6 gene expression in the reporter cells to 25.5%.

[0187] Analysis of the inflammatory effect:

[0188] Using RAW264.7 macrophages as reporter cells, IL-4 and IL-10 were first added to the culture medium to induce the reporter cells into an M2 pro-inflammatory phenotype, which essentially did not secrete pro-inflammatory cytokines. Engineered extracellular vesicles from Example 3 with a total particle count of 1E10 were added to the culture medium, and the changes in the levels of different pro-inflammatory cytokines were detected by qPCR. The results are shown in Figure 23. The engineered extracellular vesicles from Example 3 increased IL-1β expression in reporter cells to 418.7% and IL-6 expression to 315.4%. The engineered extracellular vesicles from Example 3 exhibited a highly efficient pro-inflammatory effect.

[0189] Example 4

[0190] This embodiment provides another method for preparing engineered extracellular vesicles capable of knocking down the iNOS gene. The extracellular vesicles are loaded with an iNOS guide strand RNA targeting iNOS and an iNOS guide strand RNA / NLS-AGO2 protein complex formed by NLS-AGO2 protein.

[0191] In this embodiment, the sequence shown in SEQ ID NO:3 in the expression frame of the small nucleic acid precursor expression plasmid of Example 1 is replaced with the small nucleic acid precursor expression sequence shown in SEQ ID NO:27 (21nt guide strand sequence + 17nt guest strand sequence + 88nt HDV ribozyme sequence). The NLS-AGO2 protein expression plasmid from Example 1 is used.

[0192] Except for redesigning and synthesizing the upstream primer (sequence shown in SEQ ID NO:28), downstream primer (sequence shown in SEQ ID NO:8), and template DNA (sequence shown in SEQ ID NO:27) of the small nucleic acid precursor expression plasmid according to the adjusted expression cassette, the rest were carried out in accordance with Example 1, and the engineered extracellular vesicles loaded with the iNOS guide strand RNA / NLS-AGO2 protein complex were finally obtained.

[0193] Extracellular vesicle identification:

[0194] The engineered extracellular vesicles of Example 4 were subjected to NTA analysis using a ZetaView instrument (Particle Metrix, catalog number N30E). The engineered extracellular vesicles of Example 4 were subjected to TEM analysis using transmission electron microscopy.

[0195] The particle size distribution of the engineered extracellular vesicles in Example 4 is shown in Figure 24, with an average particle size of 130.1 nm and a median particle size of 117.5 nm. As shown in Figure 25, the engineered extracellular vesicles in Example 4 exhibit typical vesicle structures.

[0196] Target gene knockdown efficiency analysis:

[0197] Using RAW264.7 macrophages as reporter cells, engineered extracellular vesicles from Example 4 with a total particle count of 1E10 were added to the culture medium. The expression level of the iNOS gene was detected by qPCR, and the results are shown in Figure 26. With iNOS gene expression in the untreated reporter cells as 100%, the engineered extracellular vesicles from Example 4 reduced iNOS gene expression in the reporter cells to 2.1%.

[0198] Analysis of the inflammatory effect in the in vivo model:

[0199] In vivo experiments were conducted using an LPS-induced acute lung injury model (C57BL / 6J mice). The engineered extracellular vesicles from Example 4 were used for testing. Modeling and nebulized drug administration to the lungs were performed according to the procedure shown in Figure 27. The dosage was 1E11 total particles per mouse. The experimental results are shown in Figure 28. In Figure 28, the blank group was normal control mice, the modeling group was control mice that received LPS intranasally without administration, and the drug administration group was experimental mice that received LPS intranasally and were also administered the drug.

[0200] Figure 28 shows that the levels of IL-12 and IFN-γ, two inflammatory cytokines, in the bronchoalveolar lavage fluid of the treatment group mice were significantly lower than those in the modeling group mice, indicating that the engineered extracellular vesicles of Example 4 can significantly reduce the level of inflammation in the lungs. Figure 29 shows that lung sections and HE staining of the modeling group mice showed a high level of lymphocyte infiltration, as well as tissue edema and thickening, while the lungs of the treatment group mice showed better improvement, manifested as reduced lymphocyte infiltration and tissue morphology closer to normal levels.

[0201] The present invention has been described in detail above, with the aim of enabling those skilled in the art to understand the content of the present invention and implement it. However, this description should not be construed as limiting the scope of protection of the present invention. Furthermore, the present invention is not limited to the above-described embodiments. All equivalent changes or modifications made in accordance with the spirit and essence of the present invention should be covered within the scope of protection of the present invention.

Claims

1. An engineered extracellular vesicle for knocking down the expression level of a target gene, characterized in that, It comprises an extracellular vesicle and a nucleic acid protein complex encapsulated in the extracellular vesicle, the nucleic acid protein complex is composed of a guide strand of a small nucleic acid, an AGO2 protein and an NLS polypeptide, the guide strand of the small nucleic acid is combined with the AGO2 protein through non-covalent interaction, the NLS polypeptide is connected at the N-terminal of the AGO2 protein, and the guide strand of the small nucleic acid is designed to specifically bind with the mRNA of the target gene through base complementary pairing.

2. The engineered extracellular vesicle of claim 1, wherein, The target gene comprises an inflammation-related gene, an immune regulation gene, and a lipid metabolism-related gene; And / or, the AGO2 protein comprises a human AGO2 protein; And / or, the NLS polypeptide comprises an NLS polypeptide capable of transporting the AGO2 protein to the nucleus after the engineered extracellular vesicle delivers the nucleic acid protein complex to the cell; And / or, the small nucleic acid is selected from siRNA, saRNA, ASO, shRNA, and miRNA; And / or, the length of the guide strand of the small nucleic acid is 18-30 nt.

3. The engineered extracellular vesicle of claim 1, wherein, The target gene comprises a Myd88 gene, a STAT6 gene, and an iNOS gene; And / or, the amino acid sequence encoding the AGO2 protein is shown as SEQ ID NO: 29; And / or, the NLS polypeptide is from the bipartite nuclear localization signal of the T antigen or nucleoplasmic protein of simian virus 40 (SV40).

4. The engineered extracellular vesicle of claim 1, wherein, The target gene is a Myd88 gene, and the sequence of the guide strand of the small nucleic acid is TTTAATAGGAATCAGTCGCTT; Or, the target gene is a STAT6 gene, and the sequence of the guide strand of the small nucleic acid is GCAGTACACTCATGGACTCTT, Or, the target gene is an iNOS gene, and the sequence of the guide strand of the small nucleic acid is CTGGATCTTGACCATCAGCTT.

5. An engineered cell for use in the preparation of the engineered extracellular vesicle of any one of claims 1 to 4, characterized in that, The engineered cell comprises a first exogenous nucleic acid fragment encoding a guide strand of a small nucleic acid, a passenger strand of a small nucleic acid, and a ribozyme with self-cleavage activity, and a second exogenous nucleic acid fragment encoding the NLS polypeptide and the AGO2 protein, the guide strand of the small nucleic acid and the passenger strand of the small nucleic acid can form a stem-loop structure through base reverse complementary pairing, and the ribozyme is connected to the 3' end of the passenger strand of the small nucleic acid.

6. The engineered cell of claim 5, wherein, The ribozyme is selected from an HDV ribozyme, a hairpin ribozyme, and a hammerhead ribozyme; And / or, the small nucleic acid is selected from siRNA, saRNA, ASO, shRNA, and miRNA; And / or, the loop in the stem-loop structure is located at one end of the stem; And / or, the length of the guide strand of the small nucleic acid is 18 to 30 nt; And / or, the passenger strand of the small nucleic acid is 3-6 nt shorter than the guide strand of the small nucleic acid; And / or, the engineered cell is selected from a fibroblast cell line, a fetal kidney cell line, a kidney cell line, a mesenchymal stem cell line, and a megakaryocyte cell line; And / or, the sequence of the second exogenous nucleic acid fragment is shown as SEQ ID NO:

6.

7. The engineered cell of claim 5, wherein, The small nucleic acid is a small nucleic acid targeting a Myd88 gene, and the sequence of the first exogenous nucleic acid fragment is shown as SEQ ID NO:

23. or, the small nucleic acid is a small nucleic acid targeting STAT6 gene, and the sequence of the first exogenous nucleic acid fragment is as shown in SEQ ID NO: 25, or, the small nucleic acid is a small nucleic acid targeting iNOS gene, and the sequence of the first exogenous nucleic acid fragment is as shown in SEQ ID NO:

27.

8. A method of producing an engineered extracellular vesicle for knocking down the expression level of a target gene according to any one of claims 1 to 4, characterized in that, It comprises the following steps: (1) constructing a small nucleic acid precursor expression plasmid and a protein expression plasmid, the expression frame of the small nucleic acid precursor expression plasmid comprises, from upstream to downstream, a promoter, a guide strand sequence of a small nucleic acid, a passenger strand sequence of the small nucleic acid, a sequence of a ribozyme with self-cleavage activity, and a terminator, the guide strand of the small nucleic acid is designed to be capable of specifically binding to the mRNA of the target gene by base complementary pairing, and the guide strand of the small nucleic acid and the passenger strand of the small nucleic acid can form a stem-loop structure by base reverse complementary pairing, the expression frame of the protein expression plasmid comprises, from upstream to downstream, a promoter, a coding sequence of a NLS polypeptide, a coding sequence of an AGO2 protein, and a terminator; (2) transfecting cells simultaneously or sequentially with the small nucleic acid precursor expression plasmid and the protein expression plasmid to obtain engineered cells; (3) culturing the engineered cells to obtain a cell culture solution; (4) separating the engineered extracellular vesicles from the cell culture solution.

9. The production method according to claim 8, characterized by, the ribozyme is selected from an HDV ribozyme, a hairpin ribozyme, and a hammerhead ribozyme; and / or, the small nucleic acid is selected from siRNA, saRNA, ASO, shRNA, and miRNA; and / or, the loop in the stem-loop structure is located at one end of the stem; and / or, the passenger strand of the small nucleic acid is 3-6 nt shorter than the guide strand of the small nucleic acid.

10. The preparation method according to claim 8, characterized in that, the plasmids used by the small nucleic acid precursor expression plasmid and the protein expression plasmid are independently eukaryotic expression plasmids or viral plasmids; and / or, the transfected cells are selected from fibroblast cell lines, embryonic kidney cell lines, kidney cell lines, mesenchymal stem cell lines, and megakaryocyte cell lines; and / or, the separation comprises one or more of ultracentrifugal separation, density gradient centrifugal separation, size exclusion chromatography separation, affinity chromatography separation, adsorption chromatography separation, bonded phase chromatography separation, immunological separation, and screening separation; and / or, the cell culture solution uses a serum-free medium.

11. The preparation method according to claim 8, characterized in that, the transfected cells are selected from CHO cells, HEK293 cells, COS cells, mammary epithelial cells, adipose mesenchymal stem cells, umbilical cord mesenchymal stem cells, and placental mesenchymal stem cells; and / or, the expression vectors used by the small nucleic acid precursor expression plasmid and the protein expression plasmid independently are pAAVS1 plasmids, pIRES plasmids, or pLENTI plasmids; and / or, the promoter of the small nucleic acid precursor expression plasmid is a U6 promoter, and the terminator is a polyT sequence; and / or, the promoter of the protein expression plasmid is a CAG promoter, and the terminator is a BgH sequence.

12. A medicament, characterized by comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof. It comprises the engineered extracellular vesicles of any one of claims 1-4.